The funding will accelerate OGI Bio’s expansion in the UK, EU, and US biotechnology sectors.

OGI Bio’s advanced bioreactors and automated systems streamline microbial growth, optimising product development in diverse sectors. Founded to address the inefficiencies of manual microbial growth, OGI Bio’s cost-effective solutions have garnered significant interest.

Alex McVey, CEO of OGI Bio, said: “With this investment, we will be launching additional modules to complement our existing market offerings and an enhanced software package that provides our customers with greater flexibility in process control.

“This will allow them to view, measure, and control their culturing processes from anywhere in the world.”

Mr McVey added: “TRICAPITAL Angels has been a crucial partner for OGI Bio since March 2022, leading the company’s first pre-seed raise alongside partners, including long-term backers Apollo Informal Investments.

“Over the past two years, TRICAPITAL Angels has continued to provide unwavering support, participating in two further financing rounds.”

TRICAPITAL Angels CEO Moray Martin said: “TRICAPITAL Angels is proud to continue our support for OGI Bio. Their innovative approach to microbial growth and analysis is transforming the biotechnology industry, and we believe they are well-positioned for significant growth.”